Alnylam Pharmaceuticals | ALNY - Cash And Equivalent


Alnylam Pharmaceuticals reported $1.71B in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 956.47M 105.02M Jun/2026
Agios Pharmaceuticals USD 99.65M 13.95M Jun/2026
Alnylam Pharmaceuticals USD 1.71B 2.46M Jun/2026
Amgen USD 13.99B 1.95B Jun/2026
Arrowhead Research USD 147.53M 54.11M Mar/2026
BioCryst Pharmaceuticals USD 154.97M 16.62M Jun/2026
BioMarin Pharmaceutical USD 874M 1.35B Jun/2026
Incyte USD 3.98B 33.45M Jun/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
Moderna USD 1.72B 185M Jun/2026
Neurocrine Biosciences USD 332.4M 65.9M Jun/2026
Novartis USD 6.88B 2.68B Mar/2026
PTC Therapeutics USD 1.05B 215.9M Jun/2026
Regeneron Pharmaceuticals USD 2.46B 506.8M Jun/2026
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sanofi EUR 5.54B 2.11B Mar/2026
Sarepta Therapeutics USD 571.15M 106.7M Jun/2026
Takeda JPY 460.98B 134.07B Jun/2026
Tectonic Therapeutic USD 236.89M 16.9M Mar/2026
Ultragenyx Pharmaceutical USD 125M 50M Jun/2026
Vertex Pharmaceuticals USD 7.85B 605.7M Jun/2026
Xencor USD 44.66M 30.49M Jun/2026